Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
Holding CMPS?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.63Last Year’s EPS
-0.53Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 09, 2021
|% Change Since: -33.12%
|Next Earnings Date:Nov 12, 2020
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial management and commercial preparation, but significant trial delays and organizational downsizing indicate challenges. While there are positive aspects to the company's progress, the delays and workforce reductions weigh heavily on the overall sentiment.Company Guidance
During the Q3 2024 earnings call for Compass Pathways, the company provided several key updates and metrics regarding ongoing trials and financials. The anticipated 6-week data disclosure for the pivotal COMP 005 trial has been delayed to Q2 2025, with a focus on maintaining trial integrity and quality. The company plans to disclose three key efficacy measures at the 6-week endpoint, including MADRS effect difference, p-value, and confidence intervals, as well as a high-level safety assessment from the DSMB. Financially, cash used in operations for Q3 was $22.2 million, with Q4 projected to increase to $37-43 million, positioning the full-year 2024 cash usage between $114-120 million. Compass holds $207 million in cash and equivalents as of September 30, 2024, with a cash runway expected to fund operations at least into 2026. Additionally, the company is undertaking a workforce reduction of approximately 30% to preserve cash in alignment with strategic changes to the Phase III trial readout timelines.Successful Cash Management
Cash and cash equivalents stood at $207 million at the end of Q3 2024, with a strategic plan to preserve cash into 2026 through organizational restructuring.
Positive Clinical Trial Insights
The washout rate from standard antidepressants is over 90%, indicating effective patient management in trials.
Commercial Preparation Advances
Efforts are underway to prepare for potential commercialization of COMP360, including establishing billing codes, DEA rescheduling, and strategic collaborations with psychiatry networks.
---
CMPS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CMPS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $6.19 | $4.76 | -23.10% |
| Aug 01, 2024 | $7.63 | $6.88 | -9.83% |
| May 08, 2024 | $8.54 | $8.50 | -0.47% |
| Feb 29, 2024 | $12.37 | $10.27 | -16.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does COMPASS Pathways (CMPS) report earnings?
COMPASS Pathways (CMPS) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is COMPASS Pathways (CMPS) earnings time?
COMPASS Pathways (CMPS) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMPS EPS forecast?
CMPS EPS forecast for the fiscal quarter 2024 (Q4) is -0.63.
---